UnicoCell Biomed Co., Ltd. was honored with the 4th "GoldenBoat Award" by the General Chamber of Commerce of the Republic of China (ROCCOC), and the award ceremony was held today (8/25) at the Hilton Hotel in New Taipei City. The competition is in the international licensing category, and the company is hoping to develop another international licensing channel by winning the award. The winners of this year's GoldenBoat Award were summoned by President Tsai Ing-wen at the Office of the President on the 16th of this month, and the company was represented by Chairwoman Yvonne Tsai.
The Phase I/II clinical trial for the treatment of degenerative knee osteoarthritis has been completed and is in the process of consultation with the relevant authorities for follow-up clinical trial planning; the Phase I/II clinical trial for the treatment of chronic kidney disease has completed recruiting patients and is pending for unblinding result. For the pre-clinical trial, t The company has also partnered with major hospitals in Taiwan to provide autologous cell therapy for degenerative knee osteoarthritis and difficult wounds, and currently hospitals with MOHW approval are Lin Kou Chang Gung Hospital, Shuang Ho Hospital, the Tri-Service General Hospital, Jing Mei Hospital, and Kaohsiung Chang Gung Hospital. In addition, the company has built a comprehensive cell banks in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) which could be supplied to reserach centers as cell starting material for the therapeutic study of various indications.
For more information about products and services offered by UnicoCell, please contact email@example.com
Award Ceremony with CEO YP Hung representing UnicoCell
The 4th GoldenBoat Award winners took group photo with President Tasi Ing-Wen